Beyond improving lung function, Orkambi (ivacaftor/lumacaftor) has potent anti-inflammatory benefits that may limit immune-related lung damage in people with…
Articles by Steve Bryson, PhD
The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for children with cystic fibrosis (CF) as…
A rare cell type that lines the airways, called pulmonary ionocytes, was successfully generated from stem cells derived from people…
Lung function decline in adults with stable cystic fibrosis (CF) was tied to high numbers of mature low-density neutrophils,…
Researchers are developing new inhalable nanoparticles designed to deliver RNA-based gene-editing therapeutics directly to the lungs, a study reports. Now…
Small changes in the shape of CFTR, the protein defective or absent in people with cystic fibrosis (CF), opened its…
Trikafta increased the production of the faulty CFTR protein in cystic fibrosis (CF) patients, but it remained in…
Exposure to traffic-related air pollution is an important predictor of early lung function decline in children and adolescents with…
Unique global changes in gene activity and protein production were linked to different types of mutations in the CFTR gene,…
Pulmonary exacerbations in adults with cystic fibrosis (CF) fall into three distinct groups based on inflammatory markers in…